Medical School · Year 4 · Critical Care · includes a quiz and discussion video
Seminar 3: Shock and Vasopressor Management
Year 4: Critical Care Elective
Learning Objectives
By the end of this seminar, students will be able to:
- Define shock as a state of tissue hypoperfusion and classify the four major shock categories based on underlying pathophysiology
- Recognize clinical and laboratory signs of shock including vital sign abnormalities, perfusion markers, and hemodynamic profiles
- Apply evidence-based resuscitation strategies for hypovolemic, cardiogenic, distributive, and obstructive shock
- Select appropriate vasopressors based on shock type and titrate to hemodynamic endpoints
- Implement corticosteroid therapy for refractory septic shock according to current evidence
- Recognize refractory shock and determine when to escalate to rescue therapies or transition to comfort care
I. Shock Classification
Shock represents a life-threatening state of circulatory failure resulting in inadequate tissue oxygen delivery relative to metabolic demands. At the cellular level, inadequate oxygen delivery leads to anaerobic metabolism, lactate production, and ultimately cellular dysfunction and death. The clinical syndrome manifests through hypotension, altered mental status, oliguria, and other signs of end-organ hypoperfusion. Early recognition and intervention are essential, as prolonged shock causes irreversible organ damage and death. The unifying feature across all shock types is the mismatch between tissue oxygen requirements and delivery.
The four major shock categories are classified according to the primary pathophysiological mechanism. Hypovolemic shock results from decreased intravascular volume leading to reduced venous return and cardiac output. Cardiogenic shock occurs when cardiac pump failure prevents adequate forward flow despite normal or elevated filling pressures. Distributive shock, most commonly from sepsis, results from pathological vasodilation causing maldistribution of blood flow and inadequate tissue perfusion despite preserved or elevated cardiac output. Obstructive shock occurs when mechanical factors external to the heart impede cardiac filling or outflow.
Hemodynamic profiles differentiate shock types and guide therapeutic intervention. Hypovolemic shock presents with low central venous pressure (CVP), low cardiac output, and elevated systemic vascular resistance (SVR) as compensatory vasoconstriction attempts to maintain blood pressure. Cardiogenic shock shows elevated CVP from pump failure with low cardiac output and high SVR. Distributive shock demonstrates low or normal CVP, high cardiac output in the hyperdynamic phase, and low SVR from pathological vasodilation. Obstructive shock presents with elevated CVP due to impaired venous return or cardiac filling, low cardiac output, and high SVR. Understanding these profiles directs therapy toward the specific physiological derangement.
Clinical recognition of shock relies on integrating vital signs, physical examination findings, and laboratory markers. Hypotension, defined as systolic blood pressure below 90 mmHg or mean arterial pressure below 65 mmHg, represents the defining hemodynamic abnormality. Tachycardia reflects compensatory sympathetic activation. Altered mental status ranging from anxiety to obtundation indicates inadequate cerebral perfusion. Oliguria with urine output below 0.5 mL/kg/hour signals renal hypoperfusion. Mottled skin with cool extremities results from peripheral vasoconstriction in some shock types. Elevated serum lactate above 2 mmol/L provides an objective marker of tissue hypoxia and anaerobic metabolism.
<image>Figure 1. Shock Classification. Panel A defines shock as tissue hypoperfusion with inadequate oxygen delivery, cellular dysfunction, lactate elevation, and end-organ dysfunction. Panel B illustrates the four shock types with their primary mechanisms: hypovolemic (decreased preload), cardiogenic (pump failure), distributive (vasodilation), and obstructive (outflow obstruction). Panel C compares hemodynamic profiles showing CVP, cardiac output, and SVR patterns for each shock type. Panel D presents clinical recognition parameters including hypotension, tachycardia, altered mental status, oliguria, skin findings, and lactate elevation.</image>
II. Hypovolemic Shock
Hypovolemic shock results from decreased intravascular volume with resultant inadequate venous return, reduced cardiac preload, and diminished cardiac output. Hemorrhagic causes include trauma, gastrointestinal bleeding, surgical blood loss, ruptured aortic aneurysm, and postpartum hemorrhage. Non-hemorrhagic causes encompass severe dehydration, vomiting and diarrhea, third-spacing from burns or pancreatitis, and excessive diuresis. The severity correlates with the degree of volume loss, with compensatory mechanisms maintaining blood pressure until approximately 30-40% of blood volume is lost. Early recognition enables intervention before irreversible shock develops.
Assessment of hypovolemic shock combines history, physical examination, and focused testing. The history should identify potential sources of volume loss including bleeding, fluid losses, or inadequate intake. Physical examination findings include flat jugular venous pressure, dry mucous membranes, delayed capillary refill, and tachycardia. In hemorrhagic shock, signs of bleeding may be obvious externally or require investigation for occult sources such as retroperitoneal or gastrointestinal hemorrhage. Laboratory findings may include elevated blood urea nitrogen to creatinine ratio suggesting prerenal azotemia and hemoconcentration, though hemoglobin may remain normal initially in acute hemorrhage before equilibration. Hemodynamic monitoring reveals low CVP and low cardiac output with compensatory elevated SVR.
Fluid resuscitation forms the cornerstone of hypovolemic shock management. Crystalloid solutions, specifically lactated Ringer's or normal saline, serve as first-line resuscitation fluids for both hemorrhagic and non-hemorrhagic hypovolemia. Initial boluses of 1-2 liters in adults are administered rapidly with reassessment of response. In hemorrhagic shock, blood product transfusion with packed red blood cells restores oxygen-carrying capacity. Massive transfusion protocols employing balanced ratios of 1:1:1 for red cells, plasma, and platelets reduce coagulopathy and improve outcomes in severe hemorrhage. Damage control resuscitation principles in trauma include permissive hypotension, minimization of crystalloid, and early blood product administration while achieving source control.
Resuscitation endpoints guide the adequacy and termination of volume replacement. Mean arterial pressure above 65 mmHg indicates restoration of adequate perfusion pressure. Urine output exceeding 0.5 mL/kg/hour reflects renal perfusion. Lactate normalization or clearance of at least 10-20% every 2 hours demonstrates improving tissue oxygenation. Heart rate reduction toward normal suggests decreased sympathetic compensation as volume status improves. Ongoing reassessment prevents both under-resuscitation with persistent hypoperfusion and over-resuscitation with volume overload complications. Failure to respond to adequate volume resuscitation prompts evaluation for ongoing losses, alternative diagnosis, or need for vasopressor support.
<image>Figure 2. Hypovolemic Shock. Panel A categorizes causes into hemorrhagic (trauma, GI bleed, surgical, ruptured aneurysm) and non-hemorrhagic (dehydration, GI losses, third-spacing, diuresis). Panel B outlines assessment findings including history of volume loss, physical examination findings of flat JVP and dry mucosa, and hemodynamic profile of low CVP and cardiac output. Panel C describes fluid resuscitation strategy with crystalloid first-line, blood products for hemorrhage, and massive transfusion protocols with 1:1:1 ratios. Panel D presents resuscitation endpoints including MAP, urine output, lactate clearance, and heart rate normalization.</image>
III. Cardiogenic Shock
Cardiogenic shock results from primary cardiac pump failure with inadequate cardiac output despite adequate or elevated filling pressures. Acute myocardial infarction represents the most common cause, with extensive left ventricular infarction causing systolic dysfunction. Arrhythmias including ventricular tachycardia, ventricular fibrillation, and rapid atrial fibrillation with poor rate control can precipitate shock. Valvular emergencies such as acute mitral regurgitation from papillary muscle rupture or acute aortic regurgitation cause acute volume overload. Mechanical complications of myocardial infarction including ventricular septal defect and free wall rupture are rapidly fatal without intervention. Acute myocarditis and decompensated cardiomyopathy represent additional etiologies.
Assessment of cardiogenic shock reveals characteristic findings of cardiac failure with systemic hypoperfusion. The history often includes chest pain, dyspnea, and symptoms of underlying cardiac disease. Physical examination demonstrates elevated jugular venous pressure, pulmonary rales from congestion, an S3 gallop, and cool, mottled extremities. Electrocardiogram may show ST-segment changes consistent with ischemia or infarction. Echocardiography is essential, revealing reduced ejection fraction, regional wall motion abnormalities, valvular dysfunction, or mechanical complications. Elevated cardiac biomarkers including troponin support myocardial injury. Brain natriuretic peptide elevation correlates with ventricular dysfunction and congestion.
Management of cardiogenic shock prioritizes identification and treatment of the underlying cause alongside hemodynamic support. Inotropic agents including dobutamine and milrinone augment cardiac contractility; dobutamine provides beta-1 agonism while milrinone acts as a phosphodiesterase inhibitor with additional vasodilatory effects. Vasopressors, particularly norepinephrine, may be needed to maintain perfusion pressure in patients with severe hypotension. Acute coronary syndrome with cardiogenic shock requires emergent coronary angiography with revascularization. Mechanical circulatory support devices including intra-aortic balloon pump (IABP), Impella, and ECMO provide temporary hemodynamic support as a bridge to recovery, decision, or definitive therapy. Excessive diuresis should be avoided in acute cardiogenic shock to maintain preload.
Specific therapies depend on the underlying etiology. ST-elevation myocardial infarction with cardiogenic shock requires emergent cardiac catheterization regardless of time from symptom onset. Arrhythmias causing hemodynamic compromise warrant urgent cardioversion for tachyarrhythmias or pacing for bradyarrhythmias. Acute severe mitral regurgitation from papillary muscle rupture requires urgent surgical repair. Ventricular septal rupture and free wall rupture are surgical emergencies. Acute myocarditis management is primarily supportive, with mechanical circulatory support for severe cases. Decompensated heart failure may require optimization of guideline-directed medical therapy along with inotropic support.
<image>Figure 3. Cardiogenic Shock. Panel A lists causes including acute MI with LV failure, arrhythmias, acute valvular emergencies, mechanical complications, myocarditis, and decompensated cardiomyopathy. Panel B describes assessment findings including elevated JVP, pulmonary rales, S3 gallop, and echocardiographic evidence of reduced function. Panel C outlines management with inotropes (dobutamine, milrinone), vasopressors for hypotension, emergent revascularization for ACS, and mechanical support options. Panel D presents etiology-specific therapies for STEMI, arrhythmias, acute valvular disease, and mechanical complications.</image>
IV. Distributive Shock from Sepsis
Sepsis represents the most common cause of distributive shock in the ICU, defined as life-threatening organ dysfunction caused by dysregulated host response to infection. The Sepsis-3 definition requires suspected or confirmed infection plus acute organ dysfunction as measured by an increase in SOFA score of 2 or more points. Septic shock is the subset of sepsis with persistent hypotension requiring vasopressors to maintain MAP of 65 mmHg or higher and serum lactate greater than 2 mmol/L despite adequate volume resuscitation. The quick SOFA (qSOFA) criteria of respiratory rate 22 or higher, altered mental status, and systolic blood pressure 100 mmHg or lower identify patients at risk for poor outcomes outside the ICU.
The sepsis bundle represents a time-sensitive protocol with mortality benefit when implemented rapidly. Within the first hour, serum lactate should be measured to assess severity and guide resuscitation. Blood cultures should be obtained before antibiotics but should not delay antimicrobial administration. Broad-spectrum antibiotics covering likely pathogens based on infection source and local resistance patterns must be administered within one hour of recognition. Within three hours, patients with hypotension or lactate of 4 mmol/L or higher should receive 30 mL/kg of crystalloid fluid resuscitation. Vasopressors are initiated for persistent hypotension not responding to fluid resuscitation.
Source control represents an essential component of sepsis management that must be addressed promptly. Abscesses require drainage, whether percutaneous or surgical depending on location and size. Bowel perforation with peritonitis requires urgent surgical intervention. Infected devices including central venous catheters, urinary catheters, and prosthetic materials should be removed when feasible. Necrotizing soft tissue infections require aggressive surgical debridement. Source control should ideally be achieved within 6-12 hours of diagnosis, as delays increase mortality. The appropriate method depends on source location, patient stability, and available expertise.
Vasopressor therapy in septic shock follows an evidence-based algorithm. Norepinephrine serves as the first-line vasopressor, providing potent alpha-1 mediated vasoconstriction with modest beta-1 inotropy. Vasopressin acting on V1 receptors is added as a second agent when norepinephrine alone is insufficient, with typical dosing of 0.03-0.04 units per minute. When cardiac dysfunction accompanies sepsis, dobutamine provides inotropic augmentation. Epinephrine serves as rescue therapy in refractory shock, providing both alpha and beta effects. This stepwise approach addresses the pathological vasodilation characterizing septic shock while supporting cardiac function when impaired.
<image>Figure 4. Distributive Shock from Sepsis. Panel A presents Sepsis-3 definitions including sepsis as infection plus organ dysfunction, septic shock requiring vasopressors and lactate above 2, and qSOFA screening criteria. Panel B outlines the sepsis bundle with hour-1 and hour-3 targets including lactate, cultures, antibiotics, fluids, and vasopressors. Panel C describes source control principles for abscesses, perforation, infected devices, and necrotizing infections with timing recommendations. Panel D illustrates the vasopressor algorithm starting with norepinephrine, adding vasopressin, then dobutamine or epinephrine as needed.</image>
V. Obstructive Shock
Obstructive shock results from mechanical impediment to cardiac filling or outflow, causing inadequate cardiac output despite normal pump function and volume status. Massive pulmonary embolism causes acute right ventricular failure from sudden increase in pulmonary vascular resistance. Tension pneumothorax impairs venous return through elevated intrathoracic pressure and mediastinal shift. Cardiac tamponade from pericardial effusion restricts diastolic filling. Constrictive pericarditis causes similar physiology through a thickened, non-compliant pericardium. Each cause requires specific intervention directed at the mechanical obstruction.
Recognition of obstructive shock requires high clinical suspicion based on the presentation and risk factors. Massive pulmonary embolism presents with sudden dyspnea, hypoxia, tachycardia, and often pleuritic chest pain; risk factors include immobility, malignancy, and prior venous thromboembolism. Tension pneumothorax causes sudden respiratory distress with absent breath sounds on the affected side, tracheal deviation away from the lesion, and distended neck veins. Cardiac tamponade classically presents with Beck's triad of hypotension, distended neck veins, and muffled heart sounds along with pulsus paradoxus exceeding 10 mmHg. Point-of-care ultrasound enables rapid bedside diagnosis of pericardial effusion, right ventricular dilation in PE, and pneumothorax.
Management of obstructive shock requires urgent treatment of the underlying mechanical cause. Tension pneumothorax requires immediate needle decompression followed by chest tube thoracostomy; treatment should not await imaging confirmation in unstable patients. Cardiac tamponade is treated with pericardiocentesis, either emergent needle drainage or surgical pericardial window depending on clinical stability and available expertise. Massive pulmonary embolism requires anticoagulation; thrombolysis is indicated for hemodynamically unstable patients. The key principle is that supportive measures including fluids and vasopressors provide only temporary stabilization while definitive treatment of the obstruction is arranged.
Massive pulmonary embolism management warrants detailed attention given its frequency and treatability. Hemodynamically unstable patients with PE should receive systemic thrombolysis unless absolute contraindications exist, as mortality benefit outweighs bleeding risk in this population. Catheter-directed therapy with local thrombolysis or mechanical thrombectomy offers an alternative for patients with contraindications to systemic lysis or intermediate-risk PE. Surgical embolectomy is reserved for patients with absolute contraindications to thrombolysis or failure of other therapies. Supportive care includes judicious fluid administration (small boluses only, as right ventricular overdistension worsens function) and vasopressor support with norepinephrine to maintain perfusion pressure.
<image>Figure 5. Obstructive Shock. Panel A lists causes including massive PE, tension pneumothorax, cardiac tamponade, and constrictive pericarditis with their mechanisms of obstruction. Panel B describes recognition features for each cause including presenting symptoms, physical findings, and point-of-care ultrasound findings. Panel C outlines urgent interventions: needle decompression for tension pneumothorax, pericardiocentesis for tamponade, and anticoagulation with consideration of thrombolysis for PE. Panel D details massive PE management including systemic thrombolysis, catheter-directed therapy, surgical embolectomy, and supportive care considerations.</image>
VI. Vasopressor Selection
Norepinephrine serves as the first-line vasopressor for most shock states requiring vasoconstriction. Its mechanism involves potent alpha-1 adrenergic receptor agonism causing arterial and venous vasoconstriction, with modest beta-1 effects providing mild inotropy. The primary hemodynamic effect is increased systemic vascular resistance with preserved or mildly increased cardiac output. Dosing typically begins at 0.1 mcg/kg/min and is titrated up to 2 mcg/kg/min or higher based on response. Side effects include peripheral digital ischemia with prolonged high-dose use and arrhythmias, though the arrhythmia rate is lower than with dopamine.
Vasopressin provides an alternative mechanism of vasoconstriction acting on V1 vascular receptors. Unlike catecholamines, vasopressin maintains efficacy in acidotic environments where catecholamine responsiveness is reduced. It is typically added as a second agent in septic shock when norepinephrine requirements exceed moderate doses. Fixed dosing of 0.03-0.04 units per minute is used rather than titration to effect. The catecholamine-sparing effect may reduce total adrenergic exposure. Vasopressin is also the pressor of choice in vasoplegic shock following cardiac surgery where catecholamine resistance is common.
Epinephrine provides balanced alpha and beta-adrenergic effects with both vasoconstriction and inotropy. It is the first-line agent for anaphylactic shock given its combination of vasoconstriction, bronchodilation, and inhibition of mediator release from mast cells. In cardiac arrest, epinephrine is the vasoactive agent of choice during resuscitation. As a second or third-line agent in refractory septic shock, epinephrine provides additional hemodynamic support. Dosing ranges from 0.1 to 1 mcg/kg/min in shock, with lower doses used for anaphylaxis (typically 0.3-0.5 mg intramuscular). Side effects include arrhythmias, lactate elevation (which complicates lactate monitoring), and mesenteric ischemia.
Additional vasoactive agents serve specific roles in shock management. Dopamine, historically common, has fallen out of favor due to increased arrhythmia rates compared to norepinephrine. Phenylephrine is a pure alpha-1 agonist without beta effects, useful when tachyarrhythmias preclude norepinephrine or in neurogenic shock requiring vasoconstriction without inotropy. Dobutamine is primarily a beta-1 agonist inotrope indicated for cardiogenic shock when augmented contractility is needed; it may cause hypotension from beta-2 vasodilation. Milrinone, a phosphodiesterase inhibitor, provides inotropy and vasodilation, useful in right ventricular failure and pulmonary hypertension.
<image>Figure 6. Vasopressor Selection. Panel A describes norepinephrine mechanism, hemodynamic effects, dosing range, and use as first-line agent for septic shock. Panel B outlines vasopressin mechanism, V1 receptor action, fixed dosing, and role as adjunct when catecholamine requirements are high. Panel C presents epinephrine with balanced alpha/beta effects, indication in anaphylaxis and refractory shock, dosing, and side effects including lactate elevation. Panel D reviews additional agents including dopamine limitations, phenylephrine as pure alpha agonist, dobutamine inotrope, and milrinone inodilator.</image>
VII. Vasopressor Management
Vascular access for vasopressor administration requires consideration of drug potency and infusion safety. Central venous access through internal jugular, subclavian, or femoral veins provides secure delivery of high concentrations without extravasation risk. Peripheral vasopressor administration can be used temporarily in emergency situations before central access is achieved, with preference for large, proximal veins in the upper extremity. Dedicated lumens for vasoactive infusions prevent inadvertent boluses from line flushing and ensure consistent delivery. Arterial line placement enables beat-to-beat blood pressure monitoring essential for titration. Continuous infusion through calibrated pumps ensures precise dosing.
Titration principles guide vasopressor adjustment to achieve hemodynamic goals while minimizing adverse effects. Initial dosing starts low with incremental increases based on response. Assessment intervals of 5-15 minutes allow sufficient time for new doses to equilibrate. Single-variable changes permit attribution of response to specific interventions. Target endpoints include MAP above 65 mmHg, with higher targets potentially needed for patients with chronic hypertension. Lactate trends and urine output provide additional indicators of adequate tissue perfusion beyond blood pressure alone. Over-titration risks tachyarrhythmias, peripheral ischemia, and splanchnic hypoperfusion.
Weaning vasopressors requires assessment of hemodynamic stability and resolution of the underlying condition. Stable hemodynamics without increasing pressor requirements for several hours suggests readiness for weaning. The principle of last-on, first-off guides weaning sequence in patients on multiple agents. Vasopressin is often weaned first given its fixed dosing, followed by gradual reduction of catecholamines. Slow weaning with monitoring for rebound hypotension prevents instability. Complete discontinuation may require several hours to days depending on initial severity and duration of shock.
Complications of vasopressor therapy require monitoring and prevention strategies. Extravasation of vasopressors, particularly norepinephrine, causes severe tissue necrosis; central venous access and regular peripheral IV site assessment prevent this complication. Cardiac arrhythmias are monitored by continuous telemetry, with dose reduction or agent change if problematic arrhythmias develop. Digital and peripheral ischemia may develop with prolonged high-dose vasoconstrictor use, necessitating monitoring of extremities for mottling, coolness, and color changes. Tachyphylaxis, requiring progressively higher doses for the same effect, may develop with prolonged infusions and signals need for evaluation of underlying conditions and consideration of additional agents.
<image>Figure 7. Vasopressor Management. Panel A addresses vascular access considerations including central venous catheter preference, peripheral use in emergencies, dedicated lumens, and arterial line monitoring. Panel B outlines titration principles including starting dose, assessment intervals, single-variable changes, and target endpoints. Panel C describes weaning approach including stability assessment, last-on first-off sequencing, gradual reduction, and monitoring for rebound. Panel D lists complications including extravasation injury, arrhythmias, peripheral ischemia, and tachyphylaxis with prevention and monitoring strategies.</image>
VIII. Corticosteroids in Shock
Indications for corticosteroid therapy in shock are supported by evidence primarily in septic shock refractory to fluids and vasopressors. Patients requiring moderate to high doses of norepinephrine despite adequate fluid resuscitation demonstrate faster shock reversal with corticosteroids. Known or suspected adrenal insufficiency, whether primary or related to critical illness, represents an additional indication. Relative adrenal insufficiency in the context of severe illness may impair the normal stress response. Anaphylactic shock also benefits from corticosteroids as adjunctive therapy to epinephrine, addressing the inflammatory component of the reaction.
Dosing follows established protocols derived from clinical trials. Hydrocortisone 200 mg daily, administered either as 50 mg every 6 hours or as a continuous infusion, represents the standard regimen for septic shock. Treatment duration is typically 7 days or until vasopressors are discontinued, whichever comes first. Tapering is generally not required for treatment courses of this length. Higher doses have not demonstrated additional benefit and carry increased side effect risk. Fludrocortisone addition was included in some trials but is not clearly necessary when hydrocortisone, which has mineralocorticoid activity, is used.
Benefits and risks of corticosteroid therapy must be weighed in clinical decision-making. Faster shock resolution with reduced vasopressor requirements and fewer vasopressor days represents the most consistent benefit. Time to shock reversal is shortened, potentially reducing complications of prolonged vasopressor use. Mortality benefit has been demonstrated in some but not all trials, with uncertainty about the magnitude of any survival advantage. Risks include hyperglycemia requiring increased insulin, neuromuscular weakness particularly with concurrent neuromuscular blockade, and potential increased infection risk, though secondary infection rates have not been significantly elevated in major trials.
The role of cosyntropin stimulation testing to diagnose adrenal insufficiency before treatment remains controversial. Historical practice included ACTH stimulation testing to identify patients with impaired cortisol response who might benefit from replacement. However, evidence shows that the response to cosyntropin does not reliably predict clinical benefit from corticosteroid therapy. Current recommendations favor treating based on clinical criteria, specifically refractory shock requiring vasopressors, rather than biochemical testing. If testing is performed, results should not delay initiation of hydrocortisone in patients meeting clinical criteria for treatment.
<image>Figure 8. Corticosteroids in Shock. Panel A lists indications including septic shock refractory to fluids and vasopressors, known or suspected adrenal insufficiency, and anaphylaxis as adjunctive therapy. Panel B outlines dosing with hydrocortisone 200 mg daily for 7 days or until off vasopressors, without need for tapering. Panel C compares benefits (faster shock resolution, reduced vasopressor days, possible mortality benefit) and risks (hyperglycemia, weakness, infection). Panel D addresses cosyntropin testing controversy, noting that clinical response does not correlate with stimulation test results and treatment should be based on clinical criteria.</image>
IX. Refractory Shock
Refractory shock is defined by persistent hypotension despite adequate fluid resuscitation and escalating vasopressor support. Persistent hypotension with MAP below 65 mmHg despite multiple vasopressors at high doses indicates treatment failure. End-organ dysfunction including worsening renal function, hepatic injury, and encephalopathy progresses despite intervention. Lactate fails to clear or continues to rise, indicating ongoing tissue hypoperfusion. High-dose vasopressor requirements, arbitrarily defined as norepinephrine equivalent doses exceeding certain thresholds, carry high mortality and define refractory shock.
Re-evaluation of the patient with refractory shock may identify treatable factors. Adequacy of source control should be reassessed, particularly in septic shock, as undrained collections or ongoing contamination prevent recovery. Volume status reassessment determines whether hypovolemia or fluid overload is present; both can perpetuate shock. The diagnosis should be reconsidered to ensure the shock type is correctly identified, as cardiogenic shock misidentified as septic shock will not respond appropriately. Additional contributing factors including adrenal insufficiency, occult bleeding, ongoing drug effects, or cardiac tamponade should be excluded.
Rescue therapies may be considered in selected patients with potentially reversible conditions. Corticosteroids should be initiated if not already in use. Methylene blue inhibits nitric oxide-mediated vasodilation and may benefit patients with refractory distributive shock; dosing is typically 1-2 mg/kg as a bolus followed by infusion. Mechanical circulatory support including IABP, Impella, or VA-ECMO can support patients with cardiogenic components or provide a bridge to recovery in potentially reversible conditions. High-dose insulin therapy has been used in refractory shock with mixed evidence. These interventions require careful patient selection and carry significant risks.
Recognition of irreversible shock and transition to comfort-focused care represents an essential skill in critical care. Multi-organ failure progressing despite maximal support indicates a dying trajectory. Discussions with family should honestly convey prognosis and explore goals of care aligned with patient values. Documentation of the clinical situation, conversations, and decision-making supports the care plan. When continuing aggressive treatment is no longer consistent with patient goals or offers no reasonable hope of benefit, transition to comfort care allows dignified death. Supporting family and staff through this transition is an integral part of ICU care.
<image>Figure 9. Refractory Shock. Panel A defines refractory shock by persistent hypotension, high-dose vasopressor requirements, worsening end-organ dysfunction, and non-clearing lactate. Panel B outlines re-evaluation steps including reassessing source control, volume status, diagnosis, and additional contributing factors. Panel C describes rescue therapies including corticosteroids, methylene blue, mechanical circulatory support, and high-dose insulin with appropriate patient selection. Panel D addresses recognition of irreversible shock and transition to comfort care with honest prognosis discussion, documentation, and family support.</image>
X. Monitoring and Outcomes
Resuscitation markers guide the adequacy of shock treatment and predict outcomes. Mean arterial pressure above 65 mmHg is the primary hemodynamic target, with higher targets potentially beneficial for patients with chronic hypertension. Lactate clearance of 10-20% every 2 hours indicates improving tissue perfusion and predicts survival; failure to clear lactate carries poor prognosis. Urine output exceeding 0.5 mL/kg/hour reflects renal perfusion. Central venous oxygen saturation (ScvO2) above 70% suggests adequate oxygen delivery relative to consumption, though its utility for guiding resuscitation has been questioned by recent trials.
Fluid responsiveness assessment prevents both under- and over-resuscitation. The passive leg raise test transiently increases venous return by elevating the legs; an increase in cardiac output of 10% or more predicts fluid responsiveness. Pulse pressure variation exceeding 13% in mechanically ventilated patients on controlled modes indicates fluid responsiveness. Inferior vena cava diameter and respiratory variation assessed by point-of-care ultrasound provide additional information about volume status. Static measures including CVP have poor predictive value for fluid responsiveness and should not be used in isolation. The goal is to identify patients who will benefit from additional fluid while avoiding harmful volume overload.
Quality metrics track sepsis care performance and enable benchmarking. Time to antibiotics is a critical process measure, with goals of administration within one hour of sepsis recognition. Sepsis bundle compliance assesses completion of all bundle elements within specified timeframes. ICU mortality for shock serves as the primary outcome measure and can be compared to predicted mortality from severity scores. Vasopressor-free days measure successful shock resolution and duration of vasoactive support. These metrics enable quality improvement initiatives and comparison across institutions.
Long-term outcomes of shock survivors extend beyond ICU discharge. Cognitive impairment affecting memory, attention, and executive function is common after critical illness and may persist for months to years. Functional decline with reduced physical capacity and independence affects quality of life and ability to return to work. Post-traumatic stress disorder occurs in a significant proportion of ICU survivors and their family members. Readmission risk is elevated in the months following discharge. Recognition of these long-term consequences informs discussions with families and guides post-discharge follow-up and rehabilitation.
<image>Figure 10. Monitoring and Outcomes. Panel A presents resuscitation markers including MAP target, lactate clearance, urine output, and ScvO2 with interpretation guidance. Panel B describes fluid responsiveness assessment methods including passive leg raise, pulse pressure variation, and IVC evaluation, emphasizing limitations of static measures. Panel C outlines quality metrics for sepsis care including time to antibiotics, bundle compliance, ICU mortality, and vasopressor-free days. Panel D addresses long-term outcomes of shock survivors including cognitive impairment, functional decline, PTSD, and readmission risk.</image>
Summary
Shock is classified into four types based on primary pathophysiology: hypovolemic (decreased volume causing low preload), cardiogenic (pump failure despite adequate filling), distributive (pathological vasodilation, most commonly sepsis), and obstructive (mechanical impediment to filling or outflow). Clinical recognition relies on hypotension, tachycardia, altered mental status, oliguria, skin perfusion changes, and elevated lactate as a marker of tissue hypoxia. Hypovolemic shock is treated with crystalloid resuscitation and blood products for hemorrhage, with endpoints of MAP above 65, urine output above 0.5 mL/kg/hour, and lactate clearance. Cardiogenic shock requires inotropic support with dobutamine or milrinone, vasopressors for hypotension, and treatment of underlying cause including emergent revascularization for acute coronary syndromes. Septic shock management follows the Surviving Sepsis Campaign bundle with hour-1 lactate, cultures, and antibiotics, hour-3 fluids, and vasopressors for fluid-refractory hypotension, along with source control. Obstructive shock requires urgent treatment of the mechanical cause: needle decompression for tension pneumothorax, pericardiocentesis for tamponade, and anticoagulation with consideration of thrombolysis for massive PE. Vasopressor selection starts with norepinephrine for most shock types, with vasopressin added for refractory cases and specific agents chosen based on pathophysiology. Administration requires central access when possible, careful titration to endpoints, and monitoring for complications. Corticosteroids with hydrocortisone 200 mg daily are indicated for septic shock refractory to fluids and vasopressors. Refractory shock warrants re-evaluation, consideration of rescue therapies, and when appropriate, transition to comfort care.
Key Terms
MAP (Mean Arterial Pressure): The average pressure in the arterial system during one cardiac cycle, calculated as (systolic + 2 x diastolic)/3, with a target above 65 mmHg in shock resuscitation.
SVR (Systemic Vascular Resistance): The resistance to blood flow in the systemic circulation, elevated in hypovolemic and cardiogenic shock due to compensatory vasoconstriction, and decreased in distributive shock.
Distributive Shock: Shock resulting from pathological vasodilation causing maldistribution of blood flow, most commonly from sepsis but also occurring in anaphylaxis, neurogenic injury, and adrenal crisis.
Vasopressor: A medication that causes vasoconstriction to increase systemic vascular resistance and raise blood pressure, including norepinephrine, vasopressin, and phenylephrine.
Inotrope: A medication that increases cardiac contractility, including dobutamine, milrinone, and epinephrine (which has both inotropic and vasopressor effects).
Lactate: A byproduct of anaerobic metabolism that accumulates in shock states due to inadequate oxygen delivery; elevation above 2 mmol/L indicates tissue hypoperfusion, and clearance predicts survival.
Septic Shock: A subset of sepsis with circulatory, cellular, and metabolic dysfunction characterized by need for vasopressors to maintain MAP of 65 mmHg or higher and lactate above 2 mmol/L despite adequate volume resuscitation.
Refractory Shock: Shock that fails to respond to standard resuscitation with fluids and multiple vasopressors, carrying high mortality and prompting consideration of rescue therapies or transition to comfort care.
This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.
